Marfan Sartan: a randomized, double-blind, placebo-controlled trial

{Aims To evaluate the benefit of adding Losartan to baseline therapy in patients with Marfan syndrome (MFS). Methods and results A double-blind, randomized, multi-centre, placebo-controlled, add on trial comparing Losartan (50 mg when < 50 kg, 100 mg otherwise) vs. placebo in patients with MFS according to Ghent criteria, age > 10 years old, and receiving standard therapy. 303 patients, mean age 29.9 years old, were randomized. The two groups were similar at baseline, 86% receiving beta-blocker therapy. The median follow-up was 3.5 years. The evolution of aortic diameter at the level of the sinuses of Valsalva was not modified by the adjunction of Losartan, with a mean increase in aortic diameter at the level of the sinuses of Valsalva of 0.44 mm/year (s.e. = 0.07) (-0.043 z/year